Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study
Open Access
- 1 January 2020
- journal article
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 22, 100161
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Renal Cancer is Not Radioresistant: Slowly but Continuing Shrinkage of the Tumor After Stereotactic Body Radiation TherapyTechnology in Cancer Research & Treatment, 2019
- Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell CarcinomaJournal of Urology, 2019
- Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic ApproachEuropean Urology Supplements, 2017
- Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma—a multicenter analysis of the German working group “Stereotactic Radiotherapy”Journal of Thoracic Disease, 2017
- Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial MetastasesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
- Cancer treatment and survivorship statistics, 2016CA: A Cancer Journal for Clinicians, 2016
- Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?Practical Radiation Oncology, 2015
- Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT)Radiation Oncology, 2015
- A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinomaActa Oncologica, 2006
- Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinomaRadiotherapy and Oncology, 2005